Document is current
Any future updates will be listed below
-
Authors
Röyter, Björn
Andréasson, Nellie
Forgo, Bianka
Källman, Jan
Ström, Jakob O.
-
Funding
Funding for this research was provided by:
Nyckelfonden – Örebro University Hospital research Foundation (OLL-789931 and OLL-880241, OLL-789931 and OLL-880241)
Research Committee at Örebro University Hospital (OLL-811301, OLL-939207 and OLL-933450, OLL-811301, OLL-939207 and OLL-933450)
Örebro University
- License Information
-
More Information
Article History
Received: 7 November 2024
Accepted: 19 May 2025
First Online: 30 May 2025
Declarations
:
: The study was approved by the Regional Ethical Review Board in Uppsala, Sweden (app. no. 2018/228). Informed written consent was obtained before inclusion from patients or their next of kin.
: Not applicable.
: Björn Röyter, Nellie Andréasson, Bianka Forgo and Jan Källman report no conflicts of interest. Jakob Ström received fees for participating in scientific advisory boards for Bayer in 2016 and 2019 and has been hired as an adjudicator in a trial initiated by Astra Zeneca in 2024.
